BA
The Boeing Company
BA has a slight edge over EMR overall, supported by stronger valuation and stronger fundamentals.
EMR
Emerson Electric Co.
EMR has lower modeled downside risk, despite its lower overall score.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
EMR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
EMR's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA has the edge over EMR in the historical PE scenario, which offers more potential upside but is not a forecast.
EMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $49.84 | -70% |
| Fair | 22x | $107 | -36% |
| Forward | 23x | $167 | — |
| Expensive | 33x | $160 | -4.2% |
| Current | 35x | $167 | — |
Historical ranges are pointers, not guarantees.
EMR's PE is in its expensive range at 35x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its fair range.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
EMR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for EMR, with profitability improving.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has returned to profit: it earned $9.66 per share over the past year, after losing money the year before.
EMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +53% |
| Q3 2026 | $4.78 | +18% |
| Q2 2026 | $4.57 | -1.7% |
| Q1 2026 | $4.33 | +3.6% |
| Q4 2025 | $4.09 | -2.4% |
| Q3 2025 | $4.04 | +18% |
| Q2 2025 | $4.65 | +56% |
| Q1 2025 | $4.18 | -78% |
| Q4 2024 | $4.19 | -78% |
EMR's earnings per share have fallen from their peak: $4.78 over the past year, against $22.92 in late 2023.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA's revenue has grown year over year for seven quarters in a row: $24.2B last quarter, up 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA's operating margin was 1.5% last quarter, up 22 points from the same quarter a year ago.
EMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2B | +7.1% |
| Q2 2026 | $4.9B | +7% |
| Q1 2026 | $4.6B | +2.9% |
| Q4 2025 | $4.3B | +4.1% |
| Q3 2025 | $4.9B | +5.1% |
| Q2 2025 | $4.6B | +3.9% |
| Q1 2025 | $4.4B | +1.3% |
| Q4 2024 | $4.2B | +1.4% |
EMR's revenue has grown year over year for 12 quarters in a row: $5.2B last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +3.2 points |
| Q4 2025 | 18% | -0.7 points |
| Q3 2025 | 16% | +1.7 points |
| Q2 2025 | 16% | +5.7 points |
| Q1 2025 | 14% | -0.7 points |
| Q4 2024 | 19% | +15 points |
EMR has the edge over BA on profitability, with a higher operating margin.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over EMR on cash flow, with more consistent year-over-year improvement.
EMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $917M | +8.9% |
| Q2 2026 | $1.3B | +35% |
| Q1 2026 | $694M | +351% |
| Q4 2025 | $602M | -13% |
| Q3 2025 | $842M | -8.1% |
| Q2 2025 | $977M | -2.1% |
| Q1 2025 | $154M | -77% |
| Q4 2024 | $694M | +105% |
EMR generated $3.5B in free cash flow over the past year, up 33% from the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
EMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +900K shares |
| 1 year | -0.8% | -4.7M shares |
| 3 years | -2.7% | -15.3M shares |
| 5 years | -6.6% | -39.8M shares |
| Available history | -8.5% | -52.1M shares |
EMR has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $102M |
| Q2 2026 | $356M |
| Q1 2026 | $292M |
| Q4 2025 | $250M |
| Q3 2025 | $20M |
| Q2 2025 | $25M |
| Q1 2025 | $223M |
| Q4 2024 | $899M |
EMR spent $1B buying back its own shares over the past year, down 14% from the year before.
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
EMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 1.1x | Healthy |
EMR has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
EMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 74.4 | Neutral |
EMR's weekly RSI is 64 (neutral) and its Stochastic is 74 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA has the edge over EMR on valuation relative to its sector.
EMR PE vs Industrials Sector
| Metric | EMR | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 24x | 45% above |
| PE % | 89 | 58 | 31 pts above |
EMR is trading at 35x earnings, a 45% premium to the Industrials sector's median of 24x.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
EMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $162.4 | 2.8% above |
| 20 week MA | $155.2 | 7.6% above |
| 50 week MA | $146.6 | 14% above |
| 100 week MA | $135.9 | 23% above |
| 200 week MA | $117.9 | 42% above |
EMR has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
EMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.5 | $80.0 | +4.5% |
| 2021 | $80.0 | $91.3 | +14% |
| 2022 | $91.3 | $95.5 | +4.7% |
| 2023 | $95.5 | $97.3 | +1.9% |
| 2024 | $97.3 | $125.7 | +29% |
| 2025 | $125.7 | $135.7 | +8% |
| 2026 YTD | $135.7 | $166.9 | +23% |
EMR has the edge over BA on returns for 2026, with the stronger performance.